Discovery Laboratories To Report 2014 Third Quarter Financial Results And Hold Conference Call On Thursday, November 6, 2014 At 9:00 A.M. Eastern Time
WARRINGTON, Pa., Oct. 29, 2014 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, will report its third quarter 2014 financial results on November 6, 2014 before the open of the U.S. financial markets.
The Company will host a live teleconference and webcast at 9:00 a.m. Eastern Time that same day. During the conference call, Discovery Labs' management will discuss the 2014 third quarter financial results along with other business updates.
The press release and the live webcast of the conference call will be available via Discovery Labs' corporate website at www.discoverylabs.com. The webcast will be made available on the events page. An archive will be available after the call at the same address until Thursday, November 20, 2014.
To participate in the live conference call, please dial (888) 346-0767 (domestic) or (412) 902-4251 (international). After placing the call, please ask to be joined into the Discovery Labs conference call. The conference call replay number is (877) 344-7529 (domestic) or (412) 317-0088 (international); please use 10054486 as the replay passcode.
About Discovery Labs
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs' technology platforms include a novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant. Discovery Labs' strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, to enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy but are currently not treated. SURFAXIN® (lucinactant) Intratracheal Suspension, Discovery Labs' first KL4 surfactant-based product, is the only available synthetic alternative to animal derived surfactants approved by the U.S. Food and Drug Administration (FDA). Full prescribing information can be found at http://www.surfaxin.com.
For more information, please visit the company's website at www.Discoverylabs.com.
SOURCE Discovery Laboratories, Inc.